Standardizing on Veeva Vault Enhances Regeneron’s Clinical and Regulatory Operations Processes

Leading biotechnology company using Veeva Vault Submissions and
Veeva Vault eTMF to support the development of new medicines

CHICAGO--(BUSINESS WIRE)--DIA 2017 Annual Meeting — Veeva
Systems
(NYSE: VEEV) today announced that Regeneron Pharmaceuticals
(NASDAQ: REGN) is standardizing on Veeva
Vault Submissions
and Veeva
Vault eTMF
to further streamline content in clinical and regulatory
operations. Veeva’s best-in-class cloud applications are helping
Regeneron to speed product development, increase collaboration, and
improve compliance.

The combination of Vault Submissions and Vault eTMF enables Regeneron to
manage common content on one platform across its regulatory and clinical
operations. For example, study protocol documents can be created once
and cross-linked between Vault Submissions and Vault eTMF to ensure
teams leverage the same, authoritative information and avoid duplicative
efforts, ultimately creating greater business efficiency.

“Regeneron is focused on translating leading-edge science into new
medicines that will change the lives of patients with serious diseases,”
said Jazz Tobaccowalla, chief information officer at Regeneron. “Veeva
provides us with the agility and speed we need to keep up with our rapid
pace of innovation and get these important treatments to market.”

Regeneron adopted Vault Submissions not only to improve process
efficiency among its regulatory team, but also to standardize authoring,
reviewing, and approving source documents with other functional areas
that previously used other methods.

“Veeva Vault Submissions enables us to do faster, more frequent
submissions and, at the same time, improve collaboration and ensure
real-time visibility between our regulatory and clinical teams,” said
Kelly Gage-Michaels, director of regulatory submission management at
Regeneron. “Leveraging Veeva innovation helped us to significantly
streamline our regulatory submissions. We completed several submissions
on the day we went live, and several more within the first two weeks.”

As a result of the success of Vault Submissions, Regeneron expanded its
use of Veeva
Vault
to include Vault eTMF to help maintain a constant state of
inspection readiness throughout its clinical trials. Regeneron
standardized on Vault eTMF to manage TMF documents, related information,
and processes in the same system, at the same time, as they are being
executed.

“Collaboration is key to our success at Regeneron. Veeva Vault eTMF
gives all of our employees and external partners a level of access and
visibility important to improve collaboration in our trial processes,”
added Andrew Allen, director of clinical development and regulatory
affairs systems at Regeneron. “Veeva Vault Submissions and Veeva Vault
eTMF also help us be inspection-ready and compliant.”

Ranked first in Science magazine’s global Top Employer survey and
third on Forbes’
25 most innovative companies
, Regeneron has built a strong
reputation through the discovery and development of novel medicines that
improve outcomes for patients with serious unmet needs.

“The Regeneron case study is a great example of the value Veeva Vault
can deliver in multiple areas of a life sciences organization,” said
Jennifer Goldsmith, senior vice president of Veeva Vault. “Creating and
managing content is a significant part of the process in bringing new
products to market. Veeva Vault is helping Regeneron share clinical and
regulatory content seamlessly between their two functions.”

In other news today, Veeva introduced preliminary findings of the Veeva
2017 Unified Clinical Operations Survey
, one of the industry’s
largest surveys of clinical operations professionals. Read today’s press
release
or download the full survey
report
. Veeva also announced that Veeva
Vault CTMS
is gaining momentum as customers unify their clinical
applications, including CTMS and eTMF. Read the press
release
to learn more.

Additional Information

For more on Veeva Vault Submissions, visit: veeva.com/Submissions

For more on Veeva Vault eTMF visit: veeva.com/eTMF

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow us @veevasystems on Twitter: twitter.com/veevasystems

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 525 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.


Contacts

Veeva Systems
Roger Villareal, 925-264-8885
roger.villareal@veeva.com
or
Veeva
Systems
Lisa Barbadora, 610-420-3413
pr@veeva.com